Immuno-Biological Laboratories Co Ltd
TSE:4570
Intrinsic Value
Immuno-Biological Laboratories Co., Ltd. engages in the manufacture and sale of antibody-related reagents and pharmaceutical products. [ Read More ]
The intrinsic value of one
Immuno-Biological Laboratories Co Ltd
stock under the Base Case scenario is
202.31
JPY.
Compared to the current market price of 467 JPY,
Immuno-Biological Laboratories Co Ltd
is
Overvalued by 57%.
Immuno-Biological Laboratories Co Ltd's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
Immuno-Biological Laboratories Co Ltd or that its price is influenced by factors unrelated to fundamentals.
Immuno-Biological Laboratories Co Ltd's market capitalization is 4.3B JPY.
Immuno-Biological Laboratories Co Ltd stock price is 467 JPY.
Immuno-Biological Laboratories Co Ltd stock (202.31 JPY) is 57% less than its price (467 JPY).
Immuno-Biological Laboratories Co Ltd stock (98.41 JPY) is 79% less than its price (467 JPY). Open DCF Valuation
Immuno-Biological Laboratories Co Ltd stock (306.21 JPY) is 34% less than its price (467 JPY). Open Relative Valuation
Immuno-Biological Laboratories Co Ltd.
Immuno-Biological Laboratories Co Ltd's Revenue has grown by 4% over the past 12 months.
Immuno-Biological Laboratories Co Ltd's ROE (Return on Equity) has increased in the last 3 years from -18% to -16%, and is approaching profitability.
Immuno-Biological Laboratories Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 5%.
Immuno-Biological Laboratories Co Ltd's Revenue has been growing by 9% per year for the last 3 years.
Immuno-Biological Laboratories Co Ltd's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -19% to 5%.
Immuno-Biological Laboratories Co Ltd's ROE (Return on Equity) for the past 12 months is negative and is equal to -16%.
Immuno-Biological Laboratories Co Ltd has positive Operating Income for the last twelve months.
Immuno-Biological Laboratories Co Ltd has negative Net Income for the last twelve months.
Immuno-Biological Laboratories Co Ltd has negative three-year average ROIC (Return on Invested Capital): -7%. The company is not efficient at using invested capital to generate operating income.
Immuno-Biological Laboratories Co Ltd has positive Gross Profit for the last twelve months.
Immuno-Biological Laboratories Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (629m JPY) than debt (226m JPY).
Immuno-Biological Laboratories Co Ltd has positive Free Cash Flow for the last twelve months.
Immuno-Biological Laboratories Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.21.
Immuno-Biological Laboratories Co Ltd has negative three-year average ROE (Return on Equity): -18%. The company is not efficient at transforming stockholders' equity into net income.
Immuno-Biological Laboratories Co Ltd's short-term assets (1B JPY) exceed its short-term liabilties (236m JPY).
Immuno-Biological Laboratories Co Ltd's long-term assets (1B JPY) exceed its long-term liabilties (335m JPY).
Immuno-Biological Laboratories Co Ltd's Altman Z-Score is very high and is equal to 9.25.
Immuno-Biological Laboratories Co Ltd earns more than enough operating income (50m JPY) to safely cover interest payments on its debt (1m JPY).
Valuation Backtest
Immuno-Biological Laboratories Co Ltd
Run backtest to discover the historical profit from buying and selling
Immuno-Biological Laboratories Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Immuno-Biological Laboratories Co Ltd
Balance Sheet Decomposition
Immuno-Biological Laboratories Co Ltd
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 629.2m |
| Receivables | 178.6m |
| Other Current Assets | 347.4m |
| Non-Current Assets | 279.1m |
| Long-Term Investments | 95.1m |
| PP&E | 118.7m |
| Other Non-Current Assets | 65.3m |
| Current Liabilities | 235.9m |
| Accounts Payable | 5.2m |
| Accrued Liabilities | 13.2m |
| Short-Term Debt | 135m |
| Other Current Liabilities | 82.5m |
| Non-Current Liabilities | 99.1m |
| Long-Term Debt | 90.8m |
| Other Non-Current Liabilities | 8.3m |
Earnings Waterfall
Immuno-Biological Laboratories Co Ltd
|
Revenue
|
788.1m
JPY
|
|
Cost of Revenue
|
-299m
JPY
|
|
Gross Profit
|
489.1m
JPY
|
|
Operating Expenses
|
-438.9m
JPY
|
|
Operating Income
|
50.2m
JPY
|
|
Other Expenses
|
-243m
JPY
|
|
Net Income
|
-192.7m
JPY
|
Free Cash Flow Analysis
Immuno-Biological Laboratories Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Immuno-Biological Laboratories Co Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Immuno-Biological Laboratories Co Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Immuno-Biological Laboratories Co Ltd's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Score
Immuno-Biological Laboratories Co Ltd's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Immuno-Biological Laboratories Co Ltd
Shareholder Return
Price
Immuno-Biological Laboratories Co Ltd
| Average Annual Return | -17.39% |
| Standard Deviation of Annual Returns | 14.6% |
| Max Drawdown | -71% |
| Market Capitalization | 4.3B JPY |
| Shares Outstanding | 9 313 500 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Immuno-Biological Laboratories Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Immuno-Biological Laboratories Co., Ltd. engages in the manufacture and sale of antibody-related reagents and pharmaceutical products. The company is headquartered in Fujioka-Shi, Gumma-Ken(Gunma-Ken) and currently employs 65 full-time employees. The company went IPO on 2007-03-02. The firm operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
Contact
IPO
Employees
Officers
The intrinsic value of one
Immuno-Biological Laboratories Co Ltd
stock under the Base Case scenario is
202.31
JPY.
Compared to the current market price of 467 JPY,
Immuno-Biological Laboratories Co Ltd
is
Overvalued by 57%.
You don't have any saved screeners yet
